Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,095 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation.
Steinberg BA, Holmes DN, Piccini JP, Ansell J, Chang P, Fonarow GC, Gersh B, Mahaffey KW, Kowey PR, Ezekowitz MD, Singer DE, Thomas L, Peterson ED, Hylek EM; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators and Patients. Steinberg BA, et al. Among authors: gersh b. J Am Heart Assoc. 2013 Nov 25;2(6):e000535. doi: 10.1161/JAHA.113.000535. J Am Heart Assoc. 2013. PMID: 24275632 Free PMC article.
Outcomes of patients with chronic renal insufficiency in the bypass angioplasty revascularization investigation.
Szczech LA, Best PJ, Crowley E, Brooks MM, Berger PB, Bittner V, Gersh BJ, Jones R, Califf RM, Ting HH, Whitlow PJ, Detre KM, Holmes D; Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Szczech LA, et al. Among authors: gersh bj. Circulation. 2002 May 14;105(19):2253-8. doi: 10.1161/01.cir.0000016051.33225.33. Circulation. 2002. PMID: 12010906 Clinical Trial.
Clinical factors that influence response to treatment strategies in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.
Curtis AB, Gersh BJ, Corley SD, DiMarco JP, Domanski MJ, Geller N, Greene HL, Kellen JC, Mickel M, Nelson JD, Rosenberg Y, Schron E, Shemanski L, Waldo AL, Wyse DG; AFFIRM Investigators. Curtis AB, et al. Among authors: gersh bj. Am Heart J. 2005 Apr;149(4):645-9. doi: 10.1016/j.ahj.2004.09.038. Am Heart J. 2005. PMID: 15990747 Clinical Trial.
Antithrombotic drug development for atrial fibrillation: proceedings, Washington, DC, July 25-27, 2005.
Jackson K, Gersh BJ, Stockbridge N, Fleming TR, Temple R, Califf RM, Connolly SJ, Wallentin L, Granger CB; Duke Clinical Research Institute/American Heart Journal Expert Meeting on Antithrombotic Drug Development for Atrial Fibrillation. Jackson K, et al. Among authors: gersh bj. Am Heart J. 2008 May;155(5):829-40. doi: 10.1016/j.ahj.2008.01.023. Am Heart J. 2008. PMID: 18440329 Review.
Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.
Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD, Gersh BJ, Granger CB, Hanna M, Horowitz J, Hylek EM, McMurray JJ, Verheugt FW, Wallentin L; ARISTOTLE Investigators. Lopes RD, et al. Among authors: gersh bj. Am Heart J. 2010 Mar;159(3):331-9. doi: 10.1016/j.ahj.2009.07.035. Am Heart J. 2010. PMID: 20211292 Clinical Trial.
Apixaban versus warfarin in patients with atrial fibrillation.
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators. Granger CB, et al. Among authors: gersh bj. N Engl J Med. 2011 Sep 15;365(11):981-92. doi: 10.1056/NEJMoa1107039. Epub 2011 Aug 27. N Engl J Med. 2011. PMID: 21870978 Free article. Clinical Trial.
Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial.
Lopes RD, Al-Khatib SM, Wallentin L, Yang H, Ansell J, Bahit MC, De Caterina R, Dorian P, Easton JD, Erol C, Ezekowitz JA, Gersh BJ, Granger CB, Hohnloser SH, Horowitz J, Hylek EM, McMurray JJ, Mohan P, Vinereanu D, Alexander JH. Lopes RD, et al. Among authors: gersh bj. Lancet. 2012 Nov 17;380(9855):1749-58. doi: 10.1016/S0140-6736(12)60986-6. Epub 2012 Oct 2. Lancet. 2012. PMID: 23036896 Clinical Trial.
1,095 results